Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Increased Efficacy of a Dendritic Cell–Based Therapeutic Cancer Vaccine With Adenosine Receptor Antagonist and Cd73 Inhibitor Publisher Pubmed



Arab S1 ; Kheshtchin N2 ; Ajami M3 ; Ashurpoor M4 ; Safvati A2 ; Namdar A2 ; Mirzaei R2 ; Mousavi Niri N5 ; Jadidiniaragh F4, 6, 7 ; Ghahremani MH1 ; Hadjati J2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Immunology, Tarbiat Modares University, Tehran, Iran
  4. 4. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Biotechnology, Faculty of Advanced Medical Sciences, Tehran Medical Branch, Islamic Azad University, Tehran, Iran
  6. 6. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  7. 7. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Tumor Biology Published:2017


Abstract

Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell–based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell–based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell–based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell–based cancer immunotherapy. © 2017, © The Author(s) 2017.
Other Related Docs
16. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
21. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)